Baird analyst Joel Beatty lowered the firm’s price target on PTC Therapeutics (PTCT) to $66 from $70 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and where PKU PDUFA date is in July.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Revenue Performance and Promising Pipeline Present Compelling Buy Opportunity
- PTC Therapeutics price target lowered to $67 from $75 at JPMorgan
- PTC Therapeutics: Strong Financial Performance and Promising Product Launches Justify Buy Rating
- PTC Therapeutics upgraded to Neutral from Sell at Citi
- PTC Therapeutics Reports Strong Q1 2025 Results